Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $112.5 million.

  • Ultragenyx Pharmaceutical's Receivables - Net rose 2062.36% to $112.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.5 million, marking a year-over-year increase of 2062.36%. This contributed to the annual value of $121.8 million for FY2024, which is 6596.4% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Receivables - Net of $112.5 million as of Q3 2025, which was up 2062.36% from $124.5 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Receivables - Net peaked at $124.5 million during Q2 2025, and registered a low of $24.7 million during Q2 2021.
  • In the last 5 years, Ultragenyx Pharmaceutical's Receivables - Net had a median value of $70.5 million in 2023 and averaged $66.5 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first plummeted by 1464.52% in 2021, then skyrocketed by 15434.15% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Receivables - Net (Quarter) stood at $28.4 million in 2021, then surged by 42.25% to $40.4 million in 2022, then soared by 81.46% to $73.4 million in 2023, then soared by 65.96% to $121.8 million in 2024, then decreased by 7.6% to $112.5 million in 2025.
  • Its last three reported values are $112.5 million in Q3 2025, $124.5 million for Q2 2025, and $98.8 million during Q1 2025.